Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yiling Lu

Showing results (171-180 of 224) with videos related to

Pageof 23
Sort By:
Cancer Research|March 18, 2016
HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF InhibitorsAnna Budina-Kolomets, Marie R Webster, Julia I-Ju Leu, et al.
Science Advances|April 26, 2017
A murine preclinical syngeneic transplantation model for breast cancer precision medicineLorenzo Federico, Zechen Chong, Dong Zhang, et al.
Cancer Cell|September 10, 2014
A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancerXiaowen Hu, Yi Feng, Dongmei Zhang, et al.
Science Translational Medicine|June 2, 2017
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancersChaoyang Sun, Yong Fang, Jun Yin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2015
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination TherapiesClemens Krepler, Min Xiao, Katrin Sproesser, et al.
Pharmacological Research|September 24, 2021
TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitorsÉrica Aparecida de Oliveira, Jagat Chauhan, Julia Rezende da Silva, et al.
Clinical Proteomics|June 22, 2011
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast CancersBryan T Hennessy, Yiling Lu, Ana Maria Gonzalez-Angulo, et al.
Plos One|July 17, 2015
Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast CancerJames E Korkola, Eric A Collisson, Laura Heiser, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2014
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancerVivian Wai Yan Lui, Noah D Peyser, Patrick Kwok-Shing Ng, et al.
Cell Reports. Medicine|December 20, 2023
PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibitionYang Li, Lacey E Dobrolecki, Christina Sallas, et al.
Pageof 23

Showing results (171-180 of 224) with videos related to

Sort By:
Pageof 23
Cancer Research|March 18, 2016
HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF InhibitorsAnna Budina-Kolomets, Marie R Webster, Julia I-Ju Leu, et al.
Science Advances|April 26, 2017
A murine preclinical syngeneic transplantation model for breast cancer precision medicineLorenzo Federico, Zechen Chong, Dong Zhang, et al.
Cancer Cell|September 10, 2014
A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancerXiaowen Hu, Yi Feng, Dongmei Zhang, et al.
Science Translational Medicine|June 2, 2017
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancersChaoyang Sun, Yong Fang, Jun Yin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2015
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination TherapiesClemens Krepler, Min Xiao, Katrin Sproesser, et al.
Pharmacological Research|September 24, 2021
TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitorsÉrica Aparecida de Oliveira, Jagat Chauhan, Julia Rezende da Silva, et al.
Clinical Proteomics|June 22, 2011
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast CancersBryan T Hennessy, Yiling Lu, Ana Maria Gonzalez-Angulo, et al.
Plos One|July 17, 2015
Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast CancerJames E Korkola, Eric A Collisson, Laura Heiser, et al.
Proceedings of the National Academy of Sciences of the United States of America|January 8, 2014
Frequent mutation of receptor protein tyrosine phosphatases provides a mechanism for STAT3 hyperactivation in head and neck cancerVivian Wai Yan Lui, Noah D Peyser, Patrick Kwok-Shing Ng, et al.
Cell Reports. Medicine|December 20, 2023
PRMT blockade induces defective DNA replication stress response and synergizes with PARP inhibitionYang Li, Lacey E Dobrolecki, Christina Sallas, et al.
Pageof 23